Cancer-Associated Thrombosis: Implications toward Health-Related Quality of Life
- 30 June 2022
- journal article
- letter
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 48 (04) , 490-496
Abstract
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a severe health problem associated with high morbidity and mortality among cancer patients. The annual incidence of VTE is estimated at around 1% in the general population.[1] Due to the hypercoagulable state in cancer patients, there is a fourfold to sevenfold increased risk of thrombosis.[1] VTE is also an independent risk factor for mortality in patients with cancer.[2] Cancer-associated thrombosis (CAT) is increasingly important due to the rising number of individuals living with cancer. Generally, subcutaneous (SC) anticoagulants have been an ideal intervention for this population and are recommended as preferred therapy.[3] However, many studies had been performed over recent years to evaluate the use of newer direct oral anticoagulants (DOACs) with positive results. Despite extensive research, the risk of bleeding and CAT recurrence is observed in this population.[4] These outcomes and prolonged use of anticoagulants have a negative impact on patients' quality of life (QOL).[5] [6] Although several studies have been published on health-related QOL (HRQOL) after DVT,[5] [6] [7] a minority were conducted within the cancer population. Little is known on how CAT will influence a cancer patient's QOL. The main goal of this study was to evaluate the HRQOL following CAT diagnosis and to investigate potential determinants of impaired HRQOL in cancer patients using EQ-5D-5L instruments. This cross-sectional study was conducted in patients aged 18 years old and above, diagnosed and treated with either SC anticoagulants or DOACs for CAT at the Institut Kanser Negara (National Cancer Institute), Putrajaya, Malaysia, between November 2019 and May 2020. The study was approved by the Ministry of Health, and Malaysia Medical Research and Ethics Committee (MREC) (MREC-NMRR-19–565–45643). A random sampling was performed from the institutional registry of CAT patients scheduled for follow-up at the Oncology outpatient clinic. Participation was voluntary and written informed consent was obtained from all patients after being briefed regarding study objectives. The QOL outcomes were measured by the EQ-5D utility index (−0.59 to 1.00) and the health status using EQ-VAS (0–100). The EQ-5D-5L was converted using the Malaysian EQ-5D value set calculator that was previously published by Shafie et al.[8] The mean value score of the two outcomes were 0.76 and 72.3, and were used as cut-off points to dichotomize the population into a high and a low group. Sociodemographic data, EQ-5D utility index and visual analogue status (EQ-VAS) were analyzed using Statistical Package for the Social Sciences (SPSS) software version 21 for descriptive, bivariate, and binary multiple logistic regression analyses. A total of 80 patients consented and participated in this study, with mean age of 53.8 (±14.3) years at CAT diagnosis. The majority of participants were diagnosed with female reproductive organ cancer (30%), followed by colorectal and breast cancer. Moreover, 89% of participants had advanced or metastatic disease. Most of the patients were diagnosed with CAT within the first 6 months of a cancer diagnosis (58%). Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 was recorded in 75% of participants. Nearly half of the patients had recurrent CAT (46%). The composite outcome of bleeding was documented in 15% of participants. The SC anticoagulants used in this study were enoxaparin, and fondaparinux, and the DOAC was rivaroxaban. [Table 1] demonstrates the sociodemographic characteristics of the study population. The most common problems related to QOL among patients with CAT were pain and/or discomfort (52%), followed by reduced mobility (45%) and impaired usual activity (45%) ([Table 2]). These results aligned with two previous studies, but these did not explicitly focus on cancer patients.[6] [9] The results of the current study concur with previous studies, which reported that cancer pain was associated with poor QOL and increased mood disturbance.[10] A numerically higher but not statistically significant proportion of patients had pain/discomfort when treated with SC anticoagulants compared with DOACs (56 vs. 49%). It is possible that SC anticoagulants were given with the intention that the anti-inflammatory effect of those agents might reduce the discomfort.[11] The mean score for the EQ-5D utility index and EQ-VAS health status in the current study was 0.76 (±0.3) and 72.3 (±17.9), respectively. The study's mean EQ-5D utility index and EQ-VAS health status were lower than the general Malaysian population (0.93, 82.22)[12] and Malaysian individuals with chronic myeloid leukemia (0.89, 81.95).[13] Our finding was in line with a previous report that confirmed the negative impact of CT on HRQOL among cancer patients.[14] Similar findings were also noted in populations without cancer.[5] [6] [14] [15] A study conducted on 883 patients found that CAT using the same instrument recorded a lower EQ-5D utility index than the present study.[16] This highlighted the importance of local data due to differences in response to the EQ-5D question between countries. Interestingly, the EQ-5D utility index (0.8 ± 0.2 vs. 0.72 ± 0.3, p = 0.3) and EQ-VAS health status (75 ± 16.3 vs. 69 ± 19.3, p = 0.2) in patients receiving DOACs were similar to SC anticoagulants ([Table 3]). The utility index in this group of patients was comparable to individuals without cancer (0.8 vs. 0.79 vs. 0.81).[6] [15] This is to date the first study exploring the effects of DOACs on QOL specifically in cancer patients. This group of drugs offers benefits over traditional anticoagulants, such as non-requirement for routine laboratory monitoring and an attractive oral route of administration. We found that ECOG PS (adjusted odds ratio [OR] 0.03; 95% confidence...Keywords
This publication has 15 references indexed in Scilit:
- What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients’ Quality of Life?Value in Health, 2018
- Health-related quality of life after deep vein thrombosisSpringerPlus, 2016
- Influence of pain severity on the quality of life in patients with head and neck cancer before antineoplastic therapyBMC Cancer, 2014
- The effect of cancer stage and treatment modality on quality of life in oropharyngeal cancerThe Laryngoscope, 2013
- Estimating Quality of Life in Acute Venous ThrombosisJAMA Internal Medicine, 2013
- A cross-sectional validation study of EQ-5D among the Malaysian adult populationQuality of Life Research, 2010
- Comparison of Population Health Status in Six European CountriesMedical Care, 2009
- Prospective Evaluation of Health-Related Quality of Life in Patients With Deep Venous ThrombosisArchives of internal medicine (1960), 2005
- The impact of venous thrombosis on quality of lifeThrombosis Research, 2004
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood, 2002